Literature DB >> 11295421

Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells.

M Yoshimoto1, A Waki, Y Yonekura, N Sadato, T Murata, N Omata, N Takahashi, M J Welch, Y Fujibayashi.   

Abstract

To reveal the metabolic fate of acetate in neoplasms that may characterize the accumulation patterns of [1-(11)C]acetate in tumors depicted by positron emission tomography. Four tumor cell lines (LS174T, RPMI2650, A2780, and A375) and fibroblasts in growing and resting states were used. In uptake experiments, cells were incubated with[1-(14)C]acetate for 40 min. [(14)C]CO(2) was measured in the tight-air chamber, and the metabolites in cells were identified by thin layer chromatography and paper chromatography. The glucose metabolic rate of each cell line was measured with [2,6-(3)H]2-deoxy-glucose (DG), and the growth activity of each cell line was estimated by measuring the incorporation of [(3)H]methyl thymidine into DNA. Compared with resting fibroblasts, all four tumor cell lines showed higher accumulation of (14)C activity from [1-(14)C]acetate. These tumor-to-normal ratios of [1-(14)C]acetate were larger than those of DG. Tumor cells incorporated (14)C activity into the lipid-soluble fraction, mostly of phosphatidylcholine and neutral lipids, more prominently than did fibroblasts. The lipid-soluble fraction of (14)C accumulation in cells showed a positive correlation with growth activity, whereas the water-soluble and CO(2) fractions did not. These findings suggest that the high tumor-to-normal ratio of [1-(14)C]acetate is mainly due to the enhanced lipid synthesis, which reflects the high growth activity of neoplasms. This in vitro study suggests that [1-(11)C]acetate is appropriate for estimating the growth activity of tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295421     DOI: 10.1016/s0969-8051(00)00195-5

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  73 in total

1.  Is 11C-choline the most appropriate tracer for prostate cancer? Against.

Authors:  Klaus Zöphel; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-02       Impact factor: 9.236

2.  The effect of fasting on PET Imaging of Hepatocellular Carcinoma.

Authors:  Nathan Tenley; David J Corn; Lewis Yuan; Zhenghong Lee
Journal:  J Cancer Ther       Date:  2013-04

3.  (11)C-acetate PET imaging in prostate cancer.

Authors:  Michael J Morris; Howard I Scher
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02       Impact factor: 9.236

4.  C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.

Authors:  Evan Y Yu; Mark Muzi; Joy A Hackenbracht; Brian B Rezvani; Jeanne M Link; Robert Bruce Montgomery; Celestia S Higano; Janet F Eary; David A Mankoff
Journal:  Clin Nucl Med       Date:  2011-03       Impact factor: 7.794

5.  Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer.

Authors:  Heiko Schöder; Seng C Ong; Victor E Reuter; Shangde Cai; Eva Burnazi; Guido Dalbagni; Steven M Larson; Bernard H Bochner
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

6.  Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.

Authors:  Nobuyuki Oyama; Yoko Hasegawa; Yasushi Kiyono; Masato Kobayashi; Yasuhisa Fujibayashi; Datta E Ponde; Carmen Dence; Michael J Welch; Osamu Yokoyama
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-09-29       Impact factor: 9.236

7.  Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review.

Authors:  Jabi Shriki; Venkatesh Murthy; Jeffrey Brown
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

8.  [11C] acetoacetate utilization by breast and prostate tumors: a PET and biodistribution study in mice.

Authors:  Simon Authier; Sébastien Tremblay; Véronique Dumulon; Céléna Dubuc; René Ouellet; Roger Lecomte; Stephen C Cunnane; François Bénard
Journal:  Mol Imaging Biol       Date:  2008-05-03       Impact factor: 3.488

Review 9.  New horizons in prostate cancer imaging.

Authors:  Gregory Ravizzini; Baris Turkbey; Karen Kurdziel; Peter L Choyke
Journal:  Eur J Radiol       Date:  2008-11-07       Impact factor: 3.528

Review 10.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.